{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:48:36Z","timestamp":1792889316706,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R44AI058375-10"],"award-info":[{"award-number":["5R44AI058375-10"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunization with\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (Pf) sporozoites under chemoprophylaxis (PfSPZ-CVac) is the most efficacious approach to malaria vaccination. Implementation is hampered by a complex chemoprophylaxis regimen and missing evidence for efficacy against heterologous infection. We report the results of a double-blinded, randomized, placebo-controlled trial of a simplified, condensed immunization regimen in malaria-naive volunteers (EudraCT-Nr: 2018-004523-36). Participants are immunized by direct venous inoculation of 1.1\u2009\u00d7\u200910\n                    <jats:sup>5<\/jats:sup>\n                    aseptic, purified, cryopreserved PfSPZ (PfSPZ Challenge) of the PfNF54 strain or normal saline (placebo) on days 1, 6 and 29, with simultaneous oral administration of 10\u2009mg\/kg chloroquine base. Primary endpoints are vaccine efficacy tested by controlled human malaria infection (CHMI) using the highly divergent, heterologous strain Pf7G8 and safety. Twelve weeks following immunization, 10\/13 participants in the vaccine group are sterilely protected against heterologous CHMI, while (5\/5) participants receiving placebo develop parasitemia (risk difference: 77%, p\u2009=\u20090.004, Boschloo\u2019s test). Immunization is well tolerated with self-limiting grade 1\u20132 headaches, pyrexia and fatigue that diminish with each vaccination. Immunization induces 18-fold higher anti-Pf circumsporozoite protein (PfCSP) antibody levels in protected than in unprotected vaccinees (p\u2009=\u20090.028). In addition anti-PfMSP2 antibodies are strongly protection-associated by protein microarray assessment. This PfSPZ-CVac regimen is highly efficacious, simple, safe, well tolerated and highly immunogenic.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-22740-w","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T06:03:29Z","timestamp":1620108209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial"],"prefix":"10.1038","volume":"12","author":[{"given":"Zita","family":"Sulyok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-0311","authenticated-orcid":false,"given":"Rolf","family":"Fendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-2720","authenticated-orcid":false,"given":"Freia-Raphaella","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Karnahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-7835","authenticated-orcid":false,"given":"Albert","family":"Lalremruata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"The T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folashade Almeine Cyntiche","family":"Adjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Klockenbring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fl\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamirat Gebru","family":"Woldearegai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-1765","authenticated-orcid":false,"given":"Carlos","family":"Lamsfus Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-6332","authenticated-orcid":false,"given":"Javier","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Rodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Egger-Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-7221","authenticated-orcid":false,"given":"Andrea","family":"Kreidenweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-2768","authenticated-orcid":false,"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"22740_CR1","unstructured":"WHO. World Malaria Report 2019 (Geneva, 2019)."},{"key":"22740_CR2","doi-asserted-by":"publisher","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"RTS, S Clinical Trials Partnership.","year":"2014","unstructured":"RTS, S. Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11, e1001685 (2014).","journal-title":"PLoS Med."},{"key":"22740_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS, S Clinical Trials Partnership.","year":"2015","unstructured":"RTS, S. Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"22740_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000441-197312000-00001","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde, D. F., McCarthy, V. C., Miller, R. M. & Hornick, R. B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266, 398\u2013403 (1973).","journal-title":"Am. J. Med. Sci."},{"key":"22740_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/0035-9203(74)90129-1","volume":"68","author":"KH Rieckmann","year":"1974","unstructured":"Rieckmann, K. H., Carson, P. E., Beaudoin, R. L., Cassells, J. S. & Sell, K. W. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 68, 258\u2013259 (1974).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"22740_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman, S. L. et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6, 97\u2013106 (2010).","journal-title":"Hum. Vaccin."},{"key":"22740_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/339409","volume":"185","author":"SL Hoffman","year":"2002","unstructured":"Hoffman, S. L. et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155\u20131164 (2002).","journal-title":"J. Infect. Dis."},{"key":"22740_CR8","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke, K. E. et al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA 114, 2711\u20132716 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22740_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko, M. S. et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498\u2013509 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"22740_CR10","doi-asserted-by":"publisher","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2, e89154 (2017).","journal-title":"JCI Insight"},{"key":"22740_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"22740_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"22740_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa0805832","volume":"361","author":"M Roestenberg","year":"2009","unstructured":"Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468\u2013477 (2009).","journal-title":"N. Engl. J. Med."},{"key":"22740_CR14","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0140-6736(11)60360-7","volume":"377","author":"M Roestenberg","year":"2011","unstructured":"Roestenberg, M. et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377, 1770\u20131776 (2011).","journal-title":"Lancet"},{"key":"22740_CR15","doi-asserted-by":"publisher","first-page":"e0124243","DOI":"10.1371\/journal.pone.0124243","volume":"10","author":"R Schats","year":"2015","unstructured":"Schats, R. et al. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS ONE 10, e0124243 (2015).","journal-title":"PLoS ONE"},{"key":"22740_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0923-4","volume":"15","author":"J Walk","year":"2017","unstructured":"Walk, J. et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial. BMC Med. 15, 168 (2017).","journal-title":"BMC Med."},{"key":"22740_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/infdis\/jiv224","volume":"212","author":"AE Dent","year":"2015","unstructured":"Dent, A. E. et al. Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya. J. Infect. Dis. 212, 1429\u20131438 (2015).","journal-title":"J. Infect. Dis."},{"key":"22740_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep03549","volume":"3","author":"PL Felgner","year":"2013","unstructured":"Felgner, P. L. et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci. Rep. 3, 3549 (2013).","journal-title":"Sci. Rep."},{"key":"22740_CR19","doi-asserted-by":"publisher","unstructured":"Kobayashi, T. et al. Distinct antibody signatures associated with different malaria transmission intensities in Zambia and Zimbabwe. mSphere 4, https:\/\/doi.org\/10.1128\/mSphereDirect.00061-19 (2019).","DOI":"10.1128\/mSphereDirect.00061-19"},{"key":"22740_CR20","doi-asserted-by":"publisher","unstructured":"Obiero, J. M. et al. Antibody biomarkers associated with sterile protection induced by controlled human malaria infection under chloroquine prophylaxis. mSphere 4, https:\/\/doi.org\/10.1128\/mSphereDirect.00027-19 (2019).","DOI":"10.1128\/mSphereDirect.00027-19"},{"key":"22740_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0708-9","volume":"12","author":"KA Moser","year":"2020","unstructured":"Moser, K. A. et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med. 12, 6 (2020).","journal-title":"Genome Med."},{"key":"22740_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0628-0","volume":"14","author":"B Mordm\u00fcller","year":"2015","unstructured":"Mordm\u00fcller, B. et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar. J. 14, 117 (2015).","journal-title":"Malar. J."},{"key":"22740_CR23","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1073\/pnas.1220360110","volume":"110","author":"EM Bijker","year":"2013","unstructured":"Bijker, E. M. et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc. Natl Acad. Sci. USA 110, 7862\u20137867 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22740_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199\u20131211 (2018).","journal-title":"Nat. Immunol."},{"key":"22740_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"22740_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","volume":"19","author":"J-P Julien","year":"2019","unstructured":"Julien, J.-P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 19, 761\u2013775 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"22740_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744.e738 (2020).","journal-title":"Immunity"},{"key":"22740_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04221-9","volume":"9","author":"A Roth","year":"2018","unstructured":"Roth, A. et al. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat. Commun. 9, 1837 (2018).","journal-title":"Nat. Commun."},{"key":"22740_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep11820","volume":"5","author":"RJ Longley","year":"2015","unstructured":"Longley, R. J. et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci. Rep. 5, 11820 (2015).","journal-title":"Sci. Rep."},{"key":"22740_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45440-4","volume":"9","author":"JS Eacret","year":"2019","unstructured":"Eacret, J. S., Gonzales, D. M., Franks, R. G. & Burns, J. M. Jr. Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody. Sci. Rep. 9, 9022 (2019).","journal-title":"Sci. Rep."},{"key":"22740_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42366-9","volume":"9","author":"H Nagaoka","year":"2019","unstructured":"Nagaoka, H. et al. PfMSA180 is a novel Plasmodium falciparum vaccine antigen that interacts with human erythrocyte integrin associated protein (CD47). Sci. Rep. 9, 5923 (2019).","journal-title":"Sci. Rep."},{"key":"22740_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0562-1","volume":"14","author":"M Bhattacharyya","year":"2015","unstructured":"Bhattacharyya, M. & Chakrabarti, S. Identification of important interacting proteins (IIPs) in Plasmodium falciparum using large-scale interaction network analysis and in-silico knock-out studies. Malar. J. 14, 70 (2015).","journal-title":"Malar. J."},{"key":"22740_CR33","doi-asserted-by":"publisher","unstructured":"Bousema, T. & Drakeley, C. Determinants of malaria transmission at the population level. Cold Spring Harb. Perspect. Med. 7, https:\/\/doi.org\/10.1101\/cshperspect.a025510 (2017).","DOI":"10.1101\/cshperspect.a025510"},{"key":"22740_CR34","unstructured":"WHO. WHO Preferred Product Characteristics (PPC) for Malaria Vaccines (WHO, Geneva, 2014)."},{"key":"22740_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0035-9203(84)90114-7","volume":"78","author":"TR Burkot","year":"1984","unstructured":"Burkot, T. R., Williams, J. L. & Schneider, I. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans. R. Soc. Trop. Med. Hyg. 78, 339\u2013341 (1984).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"22740_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep39462","volume":"6","author":"DJ Maskus","year":"2016","unstructured":"Maskus, D. J. et al. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. Sci. Rep. 6, 39462 (2016).","journal-title":"Sci. Rep."},{"key":"22740_CR37","doi-asserted-by":"publisher","unstructured":"Taghavian, O. et al. Antibody profiling by proteome microarray with multiplex isotype detection reveals overlap between human and Aotus nancymaae controlled malaria infections. Proteomics 18, https:\/\/doi.org\/10.1002\/pmic.201700277 (2018).","DOI":"10.1002\/pmic.201700277"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22740-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22740-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22740-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:55:01Z","timestamp":1669964101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22740-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22740"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22740-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.M. and P.G.K. received funding from the DZIF. The remaining authors declare no competing interests. All authors associated with Sanaria Inc. (N.K.C., A.M.,\u00a0B.K.L.S., T.L.R., and S.L.H.) have a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2518"}}